高效液相色谱-电感耦合等离子体质谱测定血浆中铂类抗癌药物

建立了高效液相色谱-电感耦合等离子体质谱快速测定血浆中顺铂、卡铂、奥沙利铂的方法。实验表明顺铂和奥沙利铂在纯水和血浆中不稳定,奥沙利铂在0.9%的NaCl中不稳定,因此采集的样品需尽快分析。提出了可通过测定顺铂、奥沙利铂色谱保留时间和卡铂的标准曲线来间接测定血浆中不稳定的顺铂和奥沙利铂含量的简化方法。方法检出限以铂计为0.04 ng/mL,顺铂、卡铂、奥沙利铂线性回归曲线的回归系数r均大于0.9995。方法的加标回收率在84%～102%之间,相对标准偏差在0.9%～6.4%之间。     

顺铂温敏载药粒子的制备表征

制备了顺铂温敏载药纳米粒子，表征其相关性质并考察不同温度下对体外肿瘤细胞的生长抑制作用。制备的两亲嵌段聚合物在水溶液中自发形成胶束结构并包裹顺铂，测定顺铂载药粒子的结构、形态、粒径及包封率、载药量、晶体状态等特性，并对顺铂的体外释放以及不同细胞系体外毒性也做了研究。载药粒子粒径为83.3 ± 4.3 nm，载药量为37.8%，包封率为77.8%。血清中相变温度39.3 ℃。载药颗粒在单纯化疗时细胞抑制率较小，加热后抑制作用明显增加(P<0.01)，与游离药物相近(P>0.5)。顺铂载药纳米粒子具有较好的温控特性，为顺铂在肿瘤热靶向治疗中的应用提供了一条新的途径。     

符合经典构效关系的抗肿瘤铂类药物

综述了自顺铂、卡铂后符合经典构效关系的铂类抗肿瘤药物的发展概况，按载体配基和离去基团的结构特征进行了分类，总结了各类配合物的构效关系和临床进展，其中重点对手性二胺配体的铂(Ⅱ)配合物进行了介绍。并讨论了顺铂、卡铂、奥沙利铂的作用机理。     

电感耦合等离子体原子发射光谱测定铂钯渣中铂、钯含量

铂钯属于贵金属,对于冶炼企业而言,有效回收铂钯,可以提高生产经营单位的经济效益。本文针对某铜冶炼企业工艺中产生的铂钯渣中铂、钯含量较高、难以溶解、不宜直接测定等问题,研究了一种测定铂、钯含量的新方法。首先对铂钯渣样品进行火试金熔融、富集,溶解,再用电感耦合等离子体原子发射光谱仪 (ICP-AES) 测定,方法精密度和准确度好。     

尺寸排阻色谱-电感耦合等离子体质谱联用技术研究牛血清白蛋白与顺铂的反应动力学

顺铂是广泛应用的抗肿瘤药物,生理盐水稀释后通过静脉注射到体内.研究顺铂和血浆蛋白间的相互作用对理解其药效十分重要.本实验利用尺寸排阻色谱-电感耦合等离子体质谱(SEC/ICP-MS)联用技术研究了顺铂和牛血清白蛋白(BSA)的反应速率常数.顺铂与BSA于37℃孵育3,6,9,17和24 h后,用SEC/ICPMS分析顺铂及顺铂-BSA复合物铂,从而计算出顺铂和BSA的反应速率常数为0.077 h-1.方法对于铂的检出限为0.19 ng/g.     

高效液相色谱法测定顺铂注射液中顺铂的含量

顺铂含量的测定方法有灼烧重量法[1]、高效液相色谱法[2,3]、络合滴定法[4]。顺铂注射液作为新剂型,其主含量顺铂的分析方法一直为省级标准,采用SnCl2显色法[5],该法所测值是二价铂化合物的总含量,对顺铂无选择性。文献上也有采用高效液相色谱法[6]的报道,但该法存在着:1.杂质峰与主峰分离度不够(Rs<1.5);2.方法重现性较差;3.对柱效要求高的缺点,其主要原因是所选色谱系统不理想。为此,本研究以高效液相色谱法测定顺铂注射液中顺铂的含量,取得了满意的结果。1　实验部分1.1　仪器和试剂SHIMADZULC 10A系统,双LC 10AD高压泵,DGU…     

黄芪口服液降低大鼠顺铂毒性作用机制的尿液代谢组学研究

采用基于液相色谱-飞行时间质谱联用(LC-TOF-MS)技术的代谢组学方法,分析大鼠尿液内源性代谢物的变化,研究黄芪口服液(HO)降低大鼠顺铂(CDDP)毒性的作用机制.采用低剂量多次腹腔注射CDDP的方法建立CDDP染毒大鼠模型,并连续给予16天HO.于第18天收集正常对照(Control)组、顺铂模型(CDDP)组和黄芪口服液(HO)组大鼠的24 h尿液, 进行LC-TOF-MS分析,以获取尿液代谢物组数据集,对所得数据进行主成分分析(PCA)和正交偏最小二乘法-判别分析(OPLS-DA)等多元统计分析,以筛选潜在生物标志物.于第20天采集大鼠血清测定肌酐和尿素氮水平.血清指标测定结果表明, HO可以显著降低CDDP染毒大鼠的肌酐和尿素氮水平(p<0.05).PCA得分图显示,3组可分别聚类,HO组位于Control组和CDDP组中间,表明HO可部分改善CDDP所致大鼠尿液代谢产物的异常变化.综合OPLS-DA分析、t检验和倍数变化分析结果,最终共筛选并初步鉴定出35个尿液代谢产物作为HO减毒相关的潜在生物标记物.代谢通路分析结果表明,HO可通过纠正体内氨基酸代谢、能量代谢和核苷酸代谢等通路的紊乱,降低CDDP所致机体毒性.     

铂与社会

铂是一种重要的贵金属，是化工、能源、石油炼制上的常用催化剂，是冶金工业制备高温电阻温度计的必须材料，是制造白金首饰的基本原料。铂的化合物——顺铂更是目前结构最简单的抗癌药物。本文概述了铂的性质、应用和工业制法，介绍了白金首饰的类型和检验方法，顺铂的抗癌机理。     

顺二氨二水合铂(Ⅱ)与生物膜磷脂反应的核磁共振研究

用NMR法研究了顺二氨二水合铂(Ⅱ)(AAP)与α-二棕搁酸磷脂酰胆碱(DPPC)的相互作用方式,以阐明在顺铂-细胞相互作用中膜磷脂的贡献。~1H及~(13)C谱表明,DPPC与AAP在CDCl_3中作用时,铂结合在DPPC的头部并引起DPPC分子中gauche向trans的构象转变。65℃测定DPPC脂质体与AAP在D_2O溶液中反应不同时间后的—(CH_3)_3、CH_a及—CH_3基团~1H的T_1值表明,铂在磷脂上的结合引起的磷脂构象变化会导致膜分子重新装配。     

顺铂耐药的分子机制

顺铂被广泛用于多种类型的实体肿瘤的临床治疗.DNA是顺铂的主要靶点,顺铂结合会导致DNA损伤并诱发细胞凋亡.然而,顺铂化疗常常受到内在的和获得性的耐药性的限制.在过去30多年里,大量的研究致力于对顺铂耐药性的理解,并且提出了几种导致顺铂耐药性的分子机制.这些机制显示顺铂的耐药性具有多因素特征.本文系统描述和讨论了顺铂的耐药性机制,包括细胞内药物积累的减少,药物去活作用的增强,DNA修复作用,DNA损伤反应和凋亡通路的变化以及一些间接信号通路的调控影响.     

Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE–ICP–MS

A capillary electrophoresis inductively coupled plasma mass spectrometry method for separation of free cisplatin from liposome-encapsulated cisplatin and protein-bound cisplatin was developed. A liposomal formulation of cisplatin based on PEGylated liposomes was used as model drug formulation. The effect of human plasma matrix on the analysis of liposome-encapsulated cisplatin and intact cisplatin was studied. The presence of 1 % of dextran and 4 mM of sodium dodecyl sulfate in HEPES buffer was demonstrated to be effective in improving the separation of liposomes and cisplatin bound to proteins in plasma. A detection limit of 41 ng/mL of platinum and a precision of 2.1 % (for 10 μg/mL of cisplatin standard) were obtained. Simultaneous measurements of phosphorous and platinum allows the simultaneous monitoring of the liposomes, liposome-encapsulated cisplatin, free cisplatin and cisplatin bound to plasma constituents in plasma samples. It was demonstrated that this approach is suitable for studies of the stability of liposome formulations as leakage of active drug from the liposomes and subsequent binding to biomolecules in plasma can be monitored. This methodology has not been reported before and will improve characterization of liposomal drugs during drug development and in studies on kinetics.

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry

A sensitive analytical method based on flameless atomic absorption spectrometry with Zeeman correction has been validated for the quantitative determination in human plasma of platinum originating from cisplatin in a liposomal source, SPI-77. The performance of the method was acceptable over a sample concentration range of 0. 125-1.25 micromol platinum/L and the lower limit of quantification was determined to be 1.25 micromol platinum/L in undiluted clinical samples. The performance data of the assay were investigated using both a calibration curve with carboplatin in plasma ultrafiltrate and diluted human plasma samples spiked with SPI-77. The recoveries, between-day and the within-day precisions of both methods of calibration were not significantly different allowing carboplatin ultrafiltrate calibration standards to be used to quantify platinum derived from SPI-77 in human plasma. Apparently, the liposomal formulation had no significant influence on the determination of platinum. The usefulness of the presented method was demonstrated in a phase I clinical and pharmacokinetic study. In addition, in vitro experiments were carried out to determine the distribution of SPI-77 in blood. The results indicated that platinum from SPI-77 mainly concentrates in plasma and that binding to and/or endocytosis in red blood cells is negligible.     

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry

A sensitive analytical method based on flameless atomic absorption spectrometry with Zeeman correction has been validated for the quantitative determination in human plasma of platinum originating from cisplatin in a liposomal source, SPI-77. The performance of the method was acceptable over a sample concentration range of 0.125–1.25 μmol platinum/L and the lower limit of quantification was determined to be 1.25 μmol platinum/L in undiluted clinical samples. The performance data of the assay were investigated using both a calibration curve with carboplatin in plasma ultrafiltrate and diluted human plasma samples spiked with SPI-77. The recoveries, between-day and the within-day precisions of both methods of calibration were not significantly different allowing carboplatin ultrafiltrate calibration standards to be used to quantify platinum derived from SPI-77 in human plasma. Apparently, the liposomal formulation had no significant influence on the determination of platinum. The usefulness of the presented method was demonstrated in a phase I clinical and pharmacokinetic study. In addition, in vitro experiments were carried out to determine the distribution of SPI-77 in blood. The results indicated that platinum from SPI-77 mainly concentrates in plasma and that binding to and/or endocytosis in red blood cells is negligible.     

Advances in Platinum Chemotherapeutics

The approved platinum(II)‐based anticancer agents cisplatin, carboplatin and oxaliplatin are widely utilised in the clinic, although with numerous disadvantages. With the aim of circumventing unwanted side‐effects, a great deal of research is being conducted in the areas of cancer‐specific targeting, drug administration and drug delivery. The targeting of platinum complexes to cancerous tissues can be achieved by the attachment of small molecules with biological significance. In addition, the administration of platinum complexes in the form of platinum(IV) allows for intracellular reduction to release the active form of the drug, cisplatin. Drug delivery includes such technologies as liposomes, dendrimers, polymers and nanotubes, with all showing promise for the delivery of platinum compounds. In this paper we highlight some of the recent advances in the field of platinum chemotherapeutics, with a focus on the technologies that attempt to utilise the cytotoxic nature of cisplatin, whilst improving drug targeting to reduce side‐effects.     

Determination of cisplatin and related platinum complexes in plasma ultrafiltrate and urine by high-performance liquid chromatography with on-line radioactivity detection

A reversed-phase ion-pair chromatographic method with on-line radioactivity detection for the simultaneous determination of 195mPt-labelled cisplatin and related platinum complexes has been developed. With this system a good resolution of various radiolabelled platinum complexes can be achieved. The detection limit of the radioactivity detector is 10 ng of cisplatin (specific activity of 15 MBq/mg cisplatin) per millilitre of urine or plasma ultrafiltrate. The detector response is independent of both the chemical structure of the platinum complexes and the matrix composition of the samples. This method may serve as a reference system for other high-performance liquid chromatographic systems with less specific and sensitive detectors.     

Self‐assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer

DNA damage repair through the nucleotide excision repair (NER) pathway is one of the major reasons for the decreased antitumor efficacy of platinum‐based anticancer drugs that have been widely applied in the clinic. Inhibiting the intrinsic NER function may enhance the antitumor activity of cisplatin and conquer cisplatin resistance. Herein, we report the design, optimization, and application of a self‐assembled lipid nanoparticle (LNP) system to simultaneously deliver a cisplatin prodrug together with siRNA targeting endonuclease xeroderma pigmentosum group F (XPF), a crucial component in the NER pathway. The LNP is able to efficiently encapsulate both the platinum prodrug and siRNA molecules with a tuned ratio. Both platinum prodrug and XPF‐targeted siRNA are efficiently carried into cells and released; the former damages DNA and the latter specifically downregulates both mRNA and protein levels of XPF to potentiate the platinum drug, leading to enhanced expression levels of apoptosis markers and improved cytotoxicity in both cisplatin‐sensitive and ‐resistant human lung cancer cells. Our results demonstrate an effective approach to utilize a multi‐targeted nanoparticle system that can specifically silence an NER‐related gene to promote apoptosis induced by cisplatin, especially in cisplatin‐refractory tumors.     

Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques

Cisplatin is for a long time in clinical use as efficient antitumor drug. The success in cisplatin-based chemotherapy, however, strongly depends on how careful the drug's dosages are monitored in order to reduce severe side-effects and overcome cellular resistance. The use of micellar electrokinetic chromatography with direct UV detection is described for the determination of intact cisplatin in human serum. The main product of drug's hydrolytic metabolism, cis-diammineaquachloroplatinum(II), was quantified using capillary zone electrophoresis in combination with indirect UV detection and on-line transient isotachophoresis preconcentration. The detection limits of platinum species studied were about 2-3 micromol l(-1) that allows the proposed methods to be applied for quantification of the administered levels of cisplatin as well as drug's active metabolite. Changes in the speciation of cisplatin occurring after intravenous administration can also be monitored using these simple and convenient CE techniques.     

GC Determination of Cisplatin in Serum and Urine of Cancer Patients after Chemotherapy as Platinum (II) Pyrrolidinedithiocarbamate Chelate

A gas chromatographic procedure has been developed for determination of cisplatin from pharmaceutical preparation, serum and urine after chemotherapy of cancer patients as platinum(II) pyrrolidinedithiocarbamate chelate. The elution was carried from the column DB-1701 (30 m × 0.32 mm i.d.) coupled with FID detection. Cu(II), Ni(II), Co(III), Mn(II), Fe(III), Zn(II) and VO(II) when present together with Pt(II) separated completely and did not affect the determination of platinum. The linear calibration curve for platinum (II) was within 1–30 μg mL^?1 with a detection limit of 300 ng mL^?1. The amount of cisplatin detected from serum and urine was 250–325 and 20–116 ng mL^?1 with relative standard deviations (RSD) of 0.8–1.2%, and 0.9–1.2%. The % recovery of Pt from serum and urine by standard addition was 98 and 98.2% with RSD 1.4 and 1.1%.     

Metallkomplexe als Antikrebsmittel

The platinum complex cisplatin is in worldwide use since 1978 as anticancer agent. Disadvantages of the cisplatin therapy are both drug resistance and severe side effects. To avoid these drawbacks several strategies have been developed in tumor research. Patients treated with second‐generation platinum complexes experience already less severe side effects. Organometallic and coordination complexes with different metals can be used to target DNA as well as overexpressed proteins and enzymes in cancer cells. In contrast, delivery systems for anticancer drugs target cancer cells, while being selectively accumulated in tumor tissue.